AngioDynamics wins expanded FDA clearance for OARtrac radiation dose monitor

AngioDynamics (NSDQ:ANGO) said late yesterday that it won expanded FDA 510(k) clearance for its OARtrac radiation dose monitoring system. With the new clearance, the Latham, N.Y.-based company’s OARtrac system is cleared for use with patient-specific, pre-calibrated Plastic Scintillating Detector sensors used during cancer treatments to monitor photon and electron radiation therapy as an adjunct to treatment planning. AngioDynamics’ OARtrac system is designed to enable the measurement and validation of targeted radiation doses to improve accuracy and allow for more informed dosing. “This expanded clearance provides us the opportunity to address an unmet need for patients in three of the most common types of radiation therapy, allowing for significantly improved outcomes. OARtrac is the type of disruptive technology that our customers value, and our team will continue to focus on creating additional pathways to help clinicians deliver the best possible treatment for their patients,” oncology senior VP Brent Boucher said in a press release. The new indication adds to previous clearance which cleared the device for use in the real-time monitoring and measurement of photon radiation and high dose rate brachytherapy during cancer treatments on the skin surface and with endorectal balloon applications, AngioDynamics said. The system is also cleared for use with photon and electron energy. In January, AngioDynamics saw shares rise after the medical devic...
Source: Mass Device - Category: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Radiosurgery/Radiation therapy Regulatory/Compliance AngioDynamics Source Type: news

Related Links:

Intraoperative radiation therapy is an emerging option for adjuvant therapy for early stage breast cancer, although it is not currently considered standard of care in the United States. We applied time-driven activity-based costing to compare two alternative methods of breast intraoperative radiation therapy, including treatment similar to the techniques employed in the TARGIT-A clinical trial and a novel version with CT-guidance and high-dose-rate (HRD) brachytherapy.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
High dose-rate (HDR) brachytherapy is commonly administered as a boost to external beam radiation therapy (EBRT). Our purpose was to compare toxicity with increasingly hypofractionated EBRT in combination with a single 15  Gy HDR boost for men with intermediate-risk prostate cancer.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: The AIRO vision implies that specific strategic interventions must be carried out in the field of national guidelines, education, research, and communication with patients and colleagues of other specialties in an interdisciplinary setting. PMID: 32190074 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
AbstractThe incidence of neuroendocrine tumours (NETs) is increasing, but curative therapeutic options are limited because diagnosis is often delayed until the tumour has metastasized. Peptide receptor radionuclide therapy (PRRT) is among the most effective therapeutic options for metastatic NETs because of targeted delivery of radioactivity to the tumour via the somatostatin receptor (SSTR) and relatively low systemic toxicity. However, current PRRT regimes result in palliation rather than cure, and higher doses of PRRT that might achieve remission would also be too toxic to the patients. Therefore, there is a need to imp...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Abstract Brachytherapy is an invasive therapy with placement of radiation source into or near the tumor. The difference between planning target volume and clinical target volume is minimal, and the dose out of the tumor reduces rapidly due to the inverse-square law. High-dose-rate brachytherapy enables three-dimensional image guidance, and currently, tumor dose as well as doses of the surrounding normal structures can be evaluated accurately. High-dose-rate brachytherapy is the utmost precision radiation therapy even surpassing carbon ion therapy. Biological disadvantages of high-dose rate have been overcome by th...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Jpn J Clin Oncol Source Type: research
Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal status of nearly 2,000 men after they had been treated for prostate cancer, or monitored with active surveillance (which entails checking the tumor periodically and treating it only if it begins to grow). Cancers in all the men were still confined to the p...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Prostate Knowledge Treatments HPK Source Type: blogs
We applaud the University of Texas Southwestern Department of Radiation Oncology for conducting “A phase II trial of stereotactic ablative radiotherapy as a boost for locally advanced cervical cancer,” a necessary prospective study on definitive dose delivery for patients unable to undergo brachytherapy.1 The involved trialists were undoubtedly deliberate and meticulous in its design and e xecution, akin to their groundbreaking work with lung stereotactic body radiation therapy (SBRT). Although these results unfortunately showed high rates of rectal toxicity, the data does not indicate a failure of SBRT, but ra...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
AbstractPurpose of the ReviewTo discuss the pivotal role of Interventional radiology (IR) for the management of colorectal liver metastases (CRLM).Recent FindingsIR has three main objectives for the treatment of CRLM:Complete tumor destruction using percutaneous ablation, as an alternative to or more frequently in combination with surgeryIntra-arterial therapies to improve objective response rate and to prolong survivalAll support therapies such as portal vein embolization or fiducial placement to allow or facilitate further treatmentsSummaryRadiofrequency ablation (RFA) is the most reported percutaneous ablation technique...
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: SIR-Spheres Y-90 resin microspheres resulted in cost savings relative to TKIs in the treatment of unresectable HCC in all four country settings, while increasing the proportion of patients who become eligible for treatments with curative intent. PMID: 32067534 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
Immunotherapy represents a promising option for treatment of hepatocellular carcinoma (HCC) in cirrhotic patients but its efficacy is currently inconsistent and unpredictable. Locoregional therapies inducing i...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Medical Devices | Radiation Therapy | Skin